GLP-1.

100 million people worldwide on Ozempic-class drugs by 2030: 50 million in the US, 30 million in India and China on generic copies, 20 million across Europe, Brazil, Japan and the Gulf. US adult obesity falls from 39.9% at the 2022 peak to 30%. 20 countries pay through public insurance. US food and drink loses $50 billion a year.

Ozempic, Wegovy, Mounjaro and Zepbound are peptides: short chains of amino acids that copy the gut hormone GLP-1, which tells your brain you are full and slows your stomach. Novo Nordisk and Eli Lilly built them for type 2 diabetes. Users lose 15 to 20% of body weight, which makes them the biggest weight-loss drugs in history.

For obesity and diabetes, yes, with limits. The SELECT trial found 20% fewer heart attacks, strokes and cardiac deaths combined, in people who already had heart disease. No trial runs past 4 years, weight returns faster after stopping, and Cochrane warns the makers funded most trials. UK regulators logged 1,176 pancreatitis reports and 18 deaths on Mounjaro alone and issued a class-wide fatal-pancreatitis warning in January 2026.

Because a peptide is cheap to copy. Fake Ozempic pens filled with insulin sent buyers in Austria and the UK to hospital. Chinese labs ship raw semaglutide powder online as "research peptides", and wellness clinics stack it with unapproved healing peptides like BPC-157. If it did not come from a pharmacy with your name on the label, do not inject it.

No. The pill treats the symptom. Fast food and processed food are the disease, and I have said so on stage for 25 years. Stop the drug and the weight comes back, while the shelf that built the appetite is still there. We built a $100 billion industry to sell the antidote to the poison, and both sides bill you monthly.

28 million Americans, 11% of US adults, are on one for weight loss, up from 3% in 2024. 1.6 million Britons bought one privately in a year. Since March 2026, when the Ozempic patent died in India, China, Brazil, Turkey and Canada, 40 Indian makers sell copies from $15 a month to 40% of the world's population.

The US, through the Medicare GLP-1 Bridge pilot from 1 July 2026 at $50 a month, plus the UK, the Netherlands and Japan under strict limits. Germany refuses: its law classes weight-loss drugs as lifestyle drugs, and a court upheld that in June 2026. My call is 20 paying countries by 2030, Germany still not among them.

Yes. 2.5 billion adults worldwide are overweight or obese in 2025, 3 billion by 2030, the number I called on stage in 2021 at 2 billion. The US is the exception: its adult obesity rate dropped from 39.9% in 2022 to 36.4% in 2026, the first fall in 50 years, tracking GLP-1 use. 100 million treated, 3 billion overweight.

Short chains of amino acids that copy a hormone. Insulin is one. Ozempic is one. Healing peptides like BPC-157, TB-500, ipamorelin and CJC-1295, the "Wolverine stack", are sold as the sequel: if a peptide can switch off hunger, another can heal your tendon, grow your muscle, slow your aging. Ozempic proved the needle. The craze sells the needle without the proof.

By 2030 healing peptides are legal by phone across the US, under tighter rules than the promoters expect, after the FDA's July 2026 panel recommended 6 of 7 for prescription compounding. Europe and the UK still ban them. BPC-157 gets its first 1,000-person trial or the market learns nobody will fund one, and the first peptide death lawsuit reaches a US court. The legal market outside GLP-1s and insulin is about $5 billion a year; the GLP-1 money, about $100 billion, is on my GLP-1 card.

Because the analysts' 7.6% a year is already behind the tape. Last year ran 7.9%, the 2 fastest sectors, wellness real estate and mental wellness, run 19.5% and 12.4%, and the models were built before 2 waves: 100 million people on GLP-1 drugs by 2030, and 1.2 billion over-60s buying prevention. $6.8 trillion at 10% a year for 6 years is $12 trillion.

The future of longevity is more healthy years, not just more years. I predict biotech, AI, diagnostics, and personalized medicine extend healthy human lifespan significantly, and the focus shifts from treating disease to preventing, delaying, and potentially reversing aging itself. People over 60 spend $19 trillion today, $40 trillion by 2036 on my call. Follow the money: Jeff Bezos backs Altos Labs, Sam Altman backs Retro Biosciences, Bryan Johnson spends $2 million a year on his own body, and Novo Nordisk and Eli Lilly now sell their weight-loss drugs as the first longevity pills. Watch who sells you the subscription: big pharma never found a cure in its life, because cures kill subscriptions. I frame longevity as several exponential technologies hitting medicine at once. The question is no longer if, but how soon, and for whom. My warning stays: no pill beats real food and a body you actually use.